DelveInsight Releases Report on Antisense Oligonucleotide Drug Development
DelveInsight has published a new report detailing over 150 companies and 200 pipeline drugs in the Antisense Oligonucleotide space. The report covers the global market and various stages of drug development.
DelveInsight has released a comprehensive report outlining the landscape of Antisense Oligonucleotide (ASO) therapeutics through 2026. The report provides in-depth insights into more than 150 companies and over 200 pipeline drugs utilizing ASO technology on a global scale.
The report details drug profiles, encompassing both clinical and non-clinical stages of development. It offers a therapeutic assessment based on product type, developmental stage, route of administration, and molecule type. Additionally, the report identifies and lists inactive pipeline products within this therapeutic area.
Antisense oligonucleotides have emerged as a significant therapeutic modality, targeting RNA for precise modulation of gene expression. This approach offers a flexible and specific strategy, particularly valuable for rare and genetic disorders. Advances in ASO technologies, including chemical modifications and delivery systems, have enhanced their stability and efficacy.
The ASO mechanism of action involves either RNA degradation or modulation of its function, such as RNase H1-mediated degradation or steric blocking. Novel delivery strategies, including nanoparticles and liposomal systems, are improving drug uptake and therapeutic potential across various diseases, such as neurological, metabolic, and cardiovascular conditions.